Fig. 2
From: Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy
Post-translational modifications of PD-L1 described in the review. AMPK: adenosine-5′-monophosphate-activated protein kinase; B3GNT3: β-1,3-N-acetylglucosaminyl transferase; CSN5: COP9 signalosome complex subunit 5; EGFR: epidermal growth factor receptor; FKBP51: FK506 binding protein 51; GSK3β: glycogen synthase kinase 3β; IL6R: interleukin-6 receptor; JAK1: Janus kinase 1; PD-L1: programmed cell death ligand 1; Sigma1: sigma nonopioid intracellular receptor 1; SPOP: speckle-type POZ protein; STT3: staurosporine temperature sensitivity 3; STUB1: STIP1 homology and U-box containing protein 1; USP22: ubiquitin-specific protease 22; ZDHHC3: zinc-finger DHHC-type-containing 3; β-TrCP: β-transducin repeat-containing protein